Savara (NASDAQ:SVRA) Announces Earnings Results

Savara (NASDAQ:SVRA) announced its earnings results on Thursday. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02), Zacks reports. The business had revenue of $0.27 million during the quarter.

Savara Stock Performance

NASDAQ:SVRA traded up $0.04 during trading hours on Friday, hitting $2.82. 60,870 shares of the company were exchanged, compared to its average volume of 1,284,818. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. Savara has a 52-week low of $2.26 and a 52-week high of $5.34. The stock has a market capitalization of $483.11 million, a price-to-earnings ratio of -6.56 and a beta of 0.60. The company’s 50 day moving average price is $2.72 and its 200-day moving average price is $3.27.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on SVRA. Wells Fargo & Company started coverage on Savara in a research note on Friday, December 20th. They set an “overweight” rating and a $8.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Savara in a research report on Friday. Finally, JMP Securities reissued a “market outperform” rating and set a $9.00 target price on shares of Savara in a research report on Thursday, December 19th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Savara currently has a consensus rating of “Moderate Buy” and an average price target of $8.83.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.